Interestingly, the possibility of targeting MT interacting proteins, the function of which is impaired in the absence of CDKL5, seems to represent an interesting disease modifying therapeutic strategy for CDD [14,15,42]. Here, CDKL5 is linked to craniodiaphyseal dysplasia.